Health and economic benefits of public financing of epilepsy treatment in India: An agent‐based simulation model

An estimated 6–10 million people in India live with active epilepsy, and less than half are treated. We analyze the health and economic benefits of three scenarios of publicly financed national epilepsy programs that provide: (1) first‐line antiepilepsy drugs (AEDs), (2) first‐ and second‐line AEDs, and (3) first‐ and second‐line AEDs and surgery.

[1]  Abigail R. Colson,et al.  Health and economic benefits of scaling up a home-based neonatal care package in rural India: a modelling analysis. , 2016, Health policy and planning.

[2]  K. Radhakrishnan,et al.  A survey of epilepsy surgery in India , 2015, Seizure.

[3]  D. Jamison,et al.  Universal public finance of tuberculosis treatment in India: an extended cost-effectiveness analysis. , 2015, Health economics.

[4]  S. Chatterjee,et al.  Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim. , 2014, Vaccine.

[5]  L. Carmant,et al.  Current beliefs and attitudes regarding epilepsy in Mali , 2014, Epilepsy & Behavior.

[6]  K. Radhakrishnan,et al.  National epilepsy surgery program: realistic goals and pragmatic solutions. , 2014, Neurology India.

[7]  S. Schachter,et al.  Drug treatment of epilepsy in adults , 2014, BMJ : British Medical Journal.

[8]  R. Glass,et al.  Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. , 2013, Vaccine.

[9]  D. Prabhakaran,et al.  An agent-based simulation modelling approach to extended cost-effectiveness analysis of health interventions , 2013, The Lancet.

[10]  Bernadette A. Thomas,et al.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[11]  P. Odermatt,et al.  Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study , 2012, The Lancet Neurology.

[12]  S. Johri,et al.  Need for a national epilepsy control program , 2012, Annals of Indian Academy of Neurology.

[13]  S. Saxena,et al.  Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study , 2012, BMJ : British Medical Journal.

[14]  R. Duncan.  Faculty Opinions recommendation of Quantifying the response to antiepileptic drugs: effect of past treatment history. , 2010 .

[15]  P. L. Lua,et al.  Awareness, knowledge and attitudes towards epilepsy among rural populations in East Coast Peninsular Malaysia: A preliminary exploration , 2010, Seizure.

[16]  Ana-Claire Meyer,et al.  Global disparities in the epilepsy treatment gap: a systematic review. , 2010, Bulletin of the World Health Organization.

[17]  Tosha B. Wetterneck,et al.  Hospital Readmission in General Medicine Patients: A Prediction Model , 2009, Journal of General Internal Medicine.

[18]  C. Newton,et al.  Packages of Care for Epilepsy in Low- and Middle-Income Countries , 2009, PLoS medicine.

[19]  A. Ngugi,et al.  The epilepsy treatment gap in developing countries: A systematic review of the magnitude, causes, and intervention strategies , 2008, Epilepsia.

[20]  Y. Schiller,et al.  Quantifying the response to antiepileptic drugs , 2008, Neurology.

[21]  S. Darley,et al.  Cost-effectiveness of Disease Interventions in India , 2007 .

[22]  O. Gureje,et al.  Cost-effectiveness of an essential mental health intervention package in Nigeria. , 2007, World psychiatry : official journal of the World Psychiatric Association.

[23]  Shekhar Saxena,et al.  Epilepsy Care in the World: Results of an ILAE/IBE/WHO Global Campaign Against Epilepsy Survey , 2006, Epilepsia.

[24]  D. Chisholm.  Cost‐effectiveness of First‐line Antiepileptic Drug Treatments in the Developing World: A Population‐level Analysis , 2005, Epilepsia.

[25]  Azeem Majeed,et al.  The Epidemiology of the Comorbidity of Epilepsy in the General Population , 2004, Epilepsia.

[26]  C. Murray,et al.  Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2003 .

[27]  Lippincott Williams Wilkins,et al.  Practice Parameter: Temporal lobe and localized neocortical resections for epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons , 2003, Neurology.

[28]  B. Vengamma,et al.  Economic Burden of Epilepsy in India , 2001, Epilepsia.

[29]  K. Radhakrishnan,et al.  Prevalence, Knowledge, Attitude, and Practice of Epilepsy in Kerala, South India , 2000, Epilepsia.

[30]  K. Radhakrishnan,et al.  Is Epilepsy Surgery Possible in Countries with Limited Resources' , 2000, Epilepsia.

[31]  R. Sridharan,et al.  Prevalence and Pattern of Epilepsy in India , 1999, Epilepsia.

[32]  W. Hauser,et al.  Remission of Seizures and Relapse in Patients with Epilepsy , 1979, Epilepsia.

[33]  P. Kwan,et al.  The need for developing comprehensive epilepsy surgery units in India , 2012 .

[34]  K. Radhakrishnan.  Epilepsy surgery in India. , 2009, Neurology India.

[35]  Jeffrey Chow,et al.  Intervention Cost-Effectiveness: Overview of Main Messages , 2006 .

[36]  P. Satishchandra,et al.  National Workshop On Public Health Aspects Of Epilepsy For Senior Personnel Of State Health Departments in India , 1999 .

[37]  T. Raju,et al.  Animal Models Of Amyotrophic Lateral Sclerosis , 1999 .